Why One PharmD Refused to
Standard PBM Oversight Isn’t Enough to Protect Your Plan
Challenges
Great client service in pharmacy benefits goes far beyond churning out utilization reports. True advocacy looks like a clinician refusing to take “no” for an answer when patient safety is on the line and putting in long hours to ensure safety and quality-of-care standards are upheld.
That is exactly what happened when Dr. Jill Sailors, PharmD, PBIRx Senior Clinical Analytical Specialist, noticed a dangerous trend buried in a routine prior authorization (PA) appeal review.
The medication was aprepitant, indicated for use to prevent post-operative nausea and vomiting (PONV) via a single capsule post-surgery, or a three-day regimen during highly emetogenic chemotherapy. Both indications are a limited quantity and short-term by design. However, the automated PA criteria utilized by one of the “Big Three” pharmacy benefit managers (PBMs) failed to reflect these prescribing boundaries. Instead, approvals were allowed for 16 capsules every 28 days, supporting months of continuous, long-term dispensing.
That gap matters because long-term use of aprepitant poses serious clinical risk, and there is a lack of safety data to support extended use. In fact, the FDA approved labeling explicitly warns against chronic administration. Because of how the drug metabolizes over time, patients with continuous exposure risk accumulated toxicity, severe drug-drug interactions, and serious adverse events. Ultimately, a flawed automated questionnaire was quietly approving a pattern of use the drug’s own safety labeling warns against.
While a typical clinical review may end once an isolated claim is cleared, Dr. Sailors recognized a systemic risk that she felt demanded intervention.
Solutions
Not Taking “No” For an Answer
When Dr. Sailors flagged the issue, the PBM’s initial peer review pushed back, ruling the existing limits were consistent with supporting literature. While many clinicians would have stopped there, Dr. Sailors advocated for this patient’s safety. She meticulously built a case by gathering manufacturer prescribing data, documenting claims history revealing months of continuous use, and drafted a formal clinical rebuttal detailing the risks of drug-drug interactions and accumulated toxicity.
The multi-month clinical challenge required rigorous internal documentation, peer-to-peer clinical accountability, and direct executive stakeholder intervention. Dr. Sailors actively monitored a member case where the drug was used continuously for several months to demonstrate real-world clinical risk. Ultimately, she escalated the matter directly to the PBM’s Executive Clinical Director and Director of Medical Affairs.
Finally, Dr. Sailors took a step that required real conviction: she issued a strict two-week deadline for the PBM to resolve the systemic oversight. If they failed to act, Dr. Sailors was prepared to file formal complaints, specifically a quality-of-care report with the National Committee for Quality Assurance (NCQA) and an official utilization management grievance with the Utilization Review Accreditation Commission (URAC).
What started as a single flagged claim ultimately required an executive-level policy review of one of the “Big Three” PBM’s national commercial book of business.
Going Above and Beyond
Dr. Sailors did not merely claim the practice was unsafe; she proved it. By anchoring her clinical and regulatory arguments with FDA labeling alongside NCQA and URAC standards, she made this case airtight. This combination of clinical rigor and structured escalation successfully elevated the issue straight to the clinical director and to Medical Affairs, ultimately forcing the PBM to overhaul and restrict the criteria for prescribing the medication.
Results
The PBM formally adopted Dr. Sailors’ recommendations, permanently rewriting the automated criteria to align with aprepitant’s actual FDA-approved indications. The revised criteria now enforce strict quantity limits for post-surgical use, while restricting prescribing authority to oncologists (or a provider in direct consultation with an oncologist) when the drug is used to prevent nausea and vomiting from emetogenic chemotherapy. This structural fix leaves no more room for chronic, off-label dosing to slip through the cracks.
The change took effect July 1, 2026, with a formal internal review scheduled for January 2027, and it protects not just PBIRx clients but the PBM’s entire national commercial membership.
This is how PBIRx clients are “informed and supported.” Upon conducting a detailed claims review, Dr. Sailors identified a systemic risk, performed the necessary clinical research and validation, and championed the initiative until permanent corrective measures were successfully instituted. Dr. Sailors mitigated severe drug-drug interactions and therapeutic duplications, extending vital clinical safety measures from a single-patient intervention to a
broad, systemic population health framework. Rigorous clinical advocacy is a standard at PBIRx, safeguarding patient care by identifying systemic gaps and refusing to compromise until a sustainable solution is finalized.
